Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elezanumab - AbbVie

Drug Profile

Elezanumab - AbbVie

Alternative Names: ABT-555

Latest Information Update: 16 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Monoclonal antibodies; Neuroprotectants; Vascular disorder therapies
  • Mechanism of Action RGMA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Spinal cord injuries; Stroke

Most Recent Events

  • 26 Oct 2022 Pooled data from two phase II trials, RADIUS-R and RADIUS-P in Relapsing and Progressive forms of multiple sclerosis were presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2022)
  • 28 Sep 2022 Elezanumab is still in phase II trial for Spinal cord injuries in Australia, Canada, Israel, Japan, South Korea, Spain, USA (IV) (NCT04295538)
  • 28 Sep 2022 Elezanumab is still in phase II trial for Acute ischaemic stroke in USA, Australia, Canada, Japan, South Korea, Spain (IV) (NCT04309474) (EudraCT2019-003753-29)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top